Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents
2016년 3월 30일 업데이트: Seema Kumar, Mayo Clinic
Vitamin D deficiency has been linked to endothelial dysfunction in adults.
Obese adolescents have a high prevalence of Vitamin D deficiency as well as evidence of endothelial dysfunction.
Our hypothesis is that supplementation of Vitamin D deficient adolescents with Vitamin D would lead to improvement in endothelial dysfunction.
연구 개요
상세 설명
Subjects had a brief screening visit with one of the study team members. Past medical history, current medications and a brief dietary history was taken. The dietary history was taken to assess calcium intake in a day and was obtained via the validated Short Calcium questionnaire. Blood pressure, heart rate as well as height,weight, waist and hip circumference measurement was obtained by study staff. In addition, a brief physical examination to determine Tanner stage was also completed. This involved examination of both breasts and genitalia for adolescent female and only genitalia in males. A physical activity questionnaire (IPAQ) was also administered by the study staff at this visit. A blood draw of 5 ml to measure plasma 25(OH) D, calcium, phosphorus was obtained as part of the screening visit. For girls who had started menstruating, a urine pregnancy test was also obtained.
After the screening visit eligible subjects had baseline biochemical tests and an endothelial function assessment. Study participants received a pill container with six total pills of vitamin cholecalciferol (D3) (1 pill = 50,000 IU), with directions to take two pills once a month (100,000 IU) at the same time for a period of 3 months. Compliance was assessed at the 3 month visit by counting the number of pills remaining in the container.
At 1 month, the subjects had tests for serum calcium and 25 hydroxy vitamin D levels. A urine test for random calcium to creatinine ratio was also obtained.
At 2 months, the serum calcium, 25 hydroxy vitamin D levels, and calcium to creatinine ratio tests were repeated.
At the end of 3 months, biochemical tests and an endothelial function assessment were repeated. Medical history, questionnaires, and the physical exam were also repeated.
연구 유형
중재적
등록 (실제)
19
단계
- 1단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- Mayo Clinic
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
12년 (어린이, 성인)
건강한 자원 봉사자를 받아들입니다
예
연구 대상 성별
모두
설명
Inclusion Criteria:
- Age 12-18 years
- BMI >95% for age and gender
- 25 (OH) D levels less than 30 ng/ml
Exclusion Criteria:
- 25 (OH) D levels >30 ng/mL
- Serum calcium >10.4 mg/dL
- Serum phosphorus > 4.7 mg/dl
- Pregnancy or nursing
- Current cancer
- Patients on vitamin D3 supplementation exceeding 400 IU/day
- Hypertension defined as Blood Pressure over the 95th percentile for age, gender and height
- Dietary calcium intake exceeding 1500 mg/day
- Hepatic or renal disorders
- Type 1 or type 2 diabetes mellitus
- Subjects receiving insulin, metformin, or oral hypoglycemic medications
- Subjects with malabsorption disorders (celiac disease, cystic fibrosis, inflammatory bowel disease)
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Vitamin D3
Vitamin D3 supplementation at 100,000 IU once a month for 3 months
|
Vitamin D 3 at 100,000 IU once a month for 3 months
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Flow Mediated Dilatation (FMD)
기간: baseline, 3 months
|
Endothelial function was assessed by FMD, via a high-resolution Doppler ultrasonography examination of the right brachial artery.
FMD was calculated as the maximal percentage increase in brachial artery diameter (BAD) from baseline after the release of cuff occlusion.
|
baseline, 3 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
25-hydroxy Vitamin D (25[OH]D) Levels
기간: baseline, 3 months
|
25(OH)D was measured using liquid chromatography-tandem mass spectrometry.
Total 25(OH)D concentrations of each sample was calculated using internal standard, 25(OH)D_2 and 25(OH)D_3.
|
baseline, 3 months
|
|
Total Cholesterol
기간: baseline, 3 months
|
Total cholesterol levels were measured by an enzymatic colorimetric assay.
|
baseline, 3 months
|
|
Triglycerides
기간: baseline, 3 months
|
Total triglyceride levels were measured by an enzymatic colorimetric assay.
|
baseline, 3 months
|
|
Body Mass Index
기간: baseline, 3 months
|
Body Mass Index (BMI) is a health index for comparing weight to height.
BMI is a person's weight in kilograms (kg) divided by his or her height in meters squared.
The body mass index is an indication if a person is at a suitable weight for his height on an approximation of body fat.
A body mass index of under 20 is considered to be underweight, while a body mass index between 20 to 25 is considered healthy.
A body mass index in the range of 25 to 30 is regarded as overweight.
A body mass index over 30 is regarded as obese.
|
baseline, 3 months
|
|
International Physical Activity Questionnaire (IPAQ) Short Form Score
기간: baseline, 3 months
|
The IPAQ short form used asked 7 questions about activities in the last 7 days, covering vigorous physical activities, moderate activities, walking, and sitting, asking for days per week, hours per day or minutes per day.
The score is reported in metabolic equivalent (MET)-minutes per week.
Possible scores could range from 0 (inactive) to greater than 3000 MET-minutes/week (highly active).
The definition of high activity was vigorous intensity activity on at least 3 days achieving a minimum total activity of at least 1500 MET-minutes/week OR 7 days of any combination of walking, moderate-intensity or vigorous-intensity activities achieving a minimum total physical activity of at least 3000 MET-minutes/week.
Therefore a score of > 3000 MET-minutes/week was possible.
|
baseline, 3 months
|
|
Calcium Intake Per Day
기간: baseline, 3 months
|
Calcium intake was measured using the validated Short Calcium Questionnaire (SCQ).
This questionnaire is in the form of an spreadsheet, and asks the participant to enter the number of servings per week of various food items and vitamin or mineral supplements.
The spreadsheet calculates the daily calcium intake (mg/day) from the data entered.
|
baseline, 3 months
|
|
Serum Parathyroid Hormone (PTH)
기간: baseline, 3 months
|
A parathyroid hormone (PTH) blood test measures the level of parathyroid hormone in the blood.
This test is used to help identify hyperparathyroidism, to find the cause of abnormal calcium levels, or to check the status of chronic kidney disease.
PTH controls calcium and phosphorus levels in the blood.
PTH was measured by a two-site chemiluminescent immunometric assay.
|
baseline, 3 months
|
|
Fasting Glucose
기간: baseline, 3 months
|
Plasma glucose was measured by hexokinase enzymatic assay.
|
baseline, 3 months
|
|
Fasting Insulin
기간: baseline, 3 months
|
Serum insulin was measured using commercial electrochemiluminescence immunoassay kits.
|
baseline, 3 months
|
|
Homeostatic Model Assessment of Insulin Resistance Index (HOMA-IR)
기간: baseline, 3 months
|
This calculation measures insulin resistance, and requires U.S. standard units.
The healthy range is 0.5 to 1.4.
Less than 1.0 means the subject is insulin-sensitive, which is optimal.
Above 1.9 indicates early insulin resistance.
Above 2.9 indicates significant insulin resistance.
The HOMA-IR was calculated as: HOMA-IR = fasting serum glucose (mmol/L) x fasting insulin (mU/mL)/22.5.
|
baseline, 3 months
|
|
High Sensitivity C-reactive Protein (Hs-CRP)
기간: baseline, 3 months
|
A high-sensitivity C-reactive protein (hs-CRP) test may be used to help evaluate an individual for risk of cardiovascular disease (CVD).
C-reactive protein (CRP) is a protein that increases in the blood with inflammation.
Studies have suggested that a persistent low level of inflammation plays a major role in atherosclerosis, the narrowing of blood vessels due to build-up of cholesterol and other lipids, which is often associated with CVD.
The hs-CRP test accurately measures low levels of C-reactive protein to identify low but persistent levels of inflammation and thus helps predict a person's risk of developing CVD.
hs-CRP was measured using particle-enhanced immunonephelometry.
|
baseline, 3 months
|
|
Low-density Lipoprotein Cholesterol (LDL) Cholesterol Levels
기간: baseline, 3 months
|
The test for low-density lipoprotein cholesterol is used as part of a lipid profile to predict an individual's risk of developing heart disease.
A desirable level is <3.36 mmol/L; borderline high is 3.36 - 4.11 mmol/L; high is >/= 4.14 mmol/L.
LDL cholesterol was calculated as: LDL = Total cholesterol - HDL cholesterol - Triglycerides/5.
|
baseline, 3 months
|
|
High Density Lipoprotein (HDL) Cholesterol Levels
기간: baseline, 3 months
|
Total HDL cholesterol levels were measured by an enzymatic colorimetric assay.
The test for high-density lipoprotein cholesterol (HDL-C) is used along with other lipid tests to screen for unhealthy levels of lipids and to determine the risk of developing heart disease.
If a subject has a negative risk factor, a desirable HDL level would be >/= 1.55 mmol/L.
|
baseline, 3 months
|
|
Urine Calcium to Creatinine Ratio
기간: baseline, 3 months
|
Urine calcium/creatinine ratio (unit mg/g) on random urine sample was calculated by dividing calcium in mg by creatinine in g.
|
baseline, 3 months
|
|
Reactive Hyperemia Index (RHI)
기간: baseline, 3 months
|
The cuff of a sphygmomanometer was placed on the forearm and inflated to 50 mm Hg above the participant's systolic blood pressure for a period of 5 min.
The increase in resting brachial blood flow was calculated as the maximum flow recorded in the first 15 seconds after cuff deflation and expressed as a percentage increase from baseline reactive.
Higher values are considered normal or improved endothelial function.
|
baseline, 3 months
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2012년 11월 1일
기본 완료 (실제)
2013년 12월 1일
연구 완료 (실제)
2013년 12월 1일
연구 등록 날짜
최초 제출
2012년 11월 16일
QC 기준을 충족하는 최초 제출
2012년 12월 6일
처음 게시됨 (추정)
2012년 12월 10일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2016년 5월 2일
QC 기준을 충족하는 마지막 업데이트 제출
2016년 3월 30일
마지막으로 확인됨
2016년 3월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Vitamin D3에 대한 임상 시험
-
Hospital Clinic of Barcelona알려지지 않은
-
Aalborg UniversityAalborg University Hospital; CCBR Aalborg A/S, Aalborg, Denmark완전한
-
Haukeland University HospitalNorwegian Foundation for Health and Rehabilitation; Foundation to Promote Research into...완전한
-
Haukeland University HospitalNorwegian Foundation for Health and Rehabilitation; Foundation to Promote Research into...완전한
-
The Affiliated Hospital of Qingdao University아직 모집하지 않음